Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t(11;14). Despite its dependence on cyclin D1 ...

1 215 728 2674 Fax: +1 215 728 3639 [email protected] Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t ...

AstraZeneca's BTK inhibitor Calquence has become the first drug in the class to be approved by the US FDA as a treatment for adult patients with previously untreated mantle cell lymphoma (MCL ...

More information: Tycel Jovelle Phillips et al, Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study, Journal of Clinical Oncology (2024). DOI: 10.1200/JCO.

for patients with mantle cell lymphoma (MCL) in remission following their initial treatment. The finding is from the phase 3 study EA4151, Rituximab With or Without Stem Cell Transplant in ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma. The EMA’s ...